Comprehensive Analysis of GABAA-A1R Developmental Alterations in Rett Syndrome: Setting the Focus for Therapeutic Targets in the Time Frame of the Disease
Authors:
- Alfonso OyarzabalAOAlfonso Oyarzabal
- Clara XiolCXClara Xiol
- Alba Aina CastellsACAlba Aina Castells
- Cristina GrauCGCristina Grau
- Mar O’callaghanMOMar O’callaghan
- Guerau FernándezGFGuerau Fernández
- Soledad AlcántaraSASoledad Alcántara
- Mercè PinedaMPMercè Pineda
- Judith ArmstrongJAJudith Armstrong
- Xavier AltafajXAXavier Altafaj
- Angels García-CazorlaAGAngels García-Cazorla
Open Access
- 14 January 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 518
Abstract
Rett syndrome, a serious neurodevelopmental disorder, has been associated with an altered expression of different synaptic-related proteins and aberrant glutamatergic and γ-aminobutyric acid (GABA)ergic neurotransmission. Despite its severity, it lacks a therapeutic option. Through this work we aimed to define the relationship between MeCP2 and GABAA.-A1 receptor expression, emphasizing the time dependence of such relationship. For this, we analyzed the expression of the ionotropic receptor subunit in different MeCP2 gene-dosage and developmental conditions, in cells lines, and in primary cultured neurons, as well as in different developmental stages of a Rett mouse model. Further, RNAseq and systems biology analysis was performed from post-mortem brain biopsies of Rett patients. We observed that the modulation of the MeCP2 expression in cellular models (both Neuro2a (N2A) cells and primary neuronal cultures) revealed a MeCP2 positive effect on the GABAA.-A1 receptor subunit expression, which did not occur in other proteins such as KCC2 (Potassium-chloride channel, member 5). In the Mecp2+/− mouse brain, both the KCC2 and GABA subunits expression were developmentally regulated, with a decreased expression during the pre-symptomatic stage, while the expression was variable in the adult symptomatic mice. Finally, the expression of the gamma-aminobutyric acid (GABA) receptor-related synaptic proteins from the postmortem brain biopsies of two Rett patients was evaluated, specifically revealing the GABA A1R subunit overexpression. The identification of the molecular changes along with the Rett syndrome prodromic stages strongly endorses the importance of time frame when addressing this disease, supporting the need for a neurotransmission-targeted early therapeutic intervention.Keywords
Funding Information
- Instituto de Salud Carlos III (PI15/01159, PI16/00851, PI15/01082)
- Mi Princesa Rett (-)
This publication has 45 references indexed in Scilit:
- Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant miceScience Translational Medicine, 2019
- Reciprocal Regulation of KCC2 Trafficking and Synaptic ActivityFrontiers in Cellular Neuroscience, 2019
- Persistent Unresolved Inflammation in theMecp2-308 Female Mutated Mouse Model of Rett SyndromeMediators of Inflammation, 2017
- Rett syndrome – biological pathways leading from MECP2 to disorder phenotypesOrphanet Journal of Rare Diseases, 2016
- MeCP2 Is Required for Normal Development of GABAergic Circuits in the ThalamusJournal of Neurophysiology, 2010
- Reversibility of functional deficits in experimental models of Rett syndromeBiochemical Society Transactions, 2010
- Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approachesBehavioural Pharmacology, 2008
- Analysis of the Set of GABAA Receptor Genes in the Human GenomeJournal of Biological Chemistry, 2004
- The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cellsJournal of Neurobiology, 2003
- A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndromeNature Genetics, 2001